NCT06046482View on ClinicalTrials.gov

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

August 26, 2024

Study Completion Date

August 26, 2024

Conditions
Head NeckSquamous Cell Carcinoma of Head and Neck
Interventions
DRUG

Pembrolizumab

Given by IV (vein)

DRUG

Magrolimab

Given by IV (vein)

DRUG

cetuximab

Given by IV (vein)

DRUG

Docetaxel

Given by IV (vein)

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER